PASSAGE BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.3 USD | -1.52% |
|
+14.04% | +28.71% |
| Mar. 04 | Passage Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 04 | Passage Bio, Inc. Appoints Kathleen Borthwick as Chief Financial Officer | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,164 | 343.6 | 75.28 | 55.37 | 80.1 | - | - |
| Enterprise Value (EV) 1 | 1,029 | 214.6 | -114.3 | -58.93 | 28.5 | 80.1 | 80.1 |
| P/E ratio | -8.79 x | -1.82 x | -0.55 x | -0.54 x | -1.06 x | -1.33 x | -1.44 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | 200 x |
| EV / Revenue | - | - | - | - | - | - | 200 x |
| EV / EBITDA | -9.18 x | -1.17 x | 0.85 x | 0.59 x | -0.38 x | -1.02 x | -1 x |
| EV / FCF | -12,604,019 x | -1,485,001 x | 948,894 x | - | - | - | - |
| FCF Yield | -0% | -0% | 0% | - | - | - | - |
| Price to Book | 3.83 x | 1.08 x | - | - | - | - | - |
| Nbr of stocks (in thousands) | 45,535 | 54,107 | 54,553 | 54,820 | 61,612 | - | - |
| Reference price 2 | 25.57 | 6.350 | 1.380 | 1.010 | 1.300 | 1.300 | 1.300 |
| Announcement Date | 3/3/21 | 3/3/22 | 3/6/23 | 3/4/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | 0.4 |
| EBITDA 1 | - | -112.1 | -184.2 | -134.7 | -99.28 | -75.23 | -78.78 | -80.46 |
| EBIT 1 | -37.19 | -112.9 | -185.7 | -138.4 | -103 | -80.28 | -91.95 | -95.9 |
| Operating Margin | - | - | - | - | - | - | - | -23,976% |
| Earnings before Tax (EBT) 1 | - | -112.2 | -185.4 | -136.1 | -102.1 | -76.65 | -89.9 | -93.98 |
| Net income 1 | - | -112.2 | -185.4 | -136.1 | -102.1 | -76.65 | -89.9 | -93.98 |
| Net margin | - | - | - | - | - | - | - | -23,494.75% |
| EPS 2 | -2.430 | -2.910 | -3.480 | -2.500 | -1.860 | -1.222 | -0.9750 | -0.9000 |
| Free Cash Flow | - | -81.67 | -144.5 | -120.5 | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/3/20 | 3/3/21 | 3/3/22 | 3/6/23 | 3/4/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | -40.83 | -50.49 | -41.93 | -38.89 | -26.6 | -27.3 | -34.9 | -24.41 | -22.32 | -17.64 | -18.46 | -18.69 | -18.92 | -19.15 |
| EBIT 1 | -47.1 | -51.16 | -42.81 | -39.81 | -27.53 | -28.24 | -35.88 | -25.39 | -23.28 | -18.45 | -19.22 | -19.58 | -20.2 | -20.47 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -46.92 | -51.15 | -42.81 | -39.54 | -26.7 | -27.07 | -34.34 | -23.86 | -27.11 | -16.76 | -17.87 | -18.28 | -18.95 | -19.32 |
| Net income 1 | -46.92 | -51.15 | -42.81 | -39.54 | -26.7 | -27.07 | -34.34 | -23.86 | -27.11 | -16.76 | -17.87 | -18.28 | -18.95 | -19.32 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.8700 | -0.9500 | -0.7900 | -0.7300 | -0.4900 | -0.4900 | -0.6300 | -0.4400 | -0.4900 | -0.3000 | -0.3400 | -0.3400 | -0.3067 | -0.2667 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 3/3/22 | 5/16/22 | 8/4/22 | 11/10/22 | 3/6/23 | 5/11/23 | 8/7/23 | 11/13/23 | 3/4/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | 135 | 129 | 190 | 114 | 51.6 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | -81.7 | -145 | -120 | - | - | - | - |
| ROE (net income / shareholders' equity) | -90.3% | -59.5% | -52.4% | - | - | - | - |
| ROA (Net income/ Total Assets) | -44.3% | -54.3% | - | - | - | - | - |
| Assets 1 | 253.3 | 341.5 | - | - | - | - | - |
| Book Value Per Share | 6.680 | 5.870 | - | - | - | - | - |
| Cash Flow per Share | - | - | -2.170 | - | - | - | - |
| Capex 1 | 1.15 | 17.6 | 2.27 | 0.15 | 4 | 4.4 | 4.8 |
| Capex / Sales | - | - | - | - | - | - | 1,200% |
| Announcement Date | 3/3/21 | 3/3/22 | 3/6/23 | 3/4/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.3
USD
Average target price
7
USD
Spread / Average Target
+438.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +28.71% | 80.1M | |
| -2.63% | 102B | |
| +1.62% | 96.29B | |
| +1.72% | 22.18B | |
| -16.67% | 21.2B | |
| -8.49% | 18.31B | |
| -38.74% | 17.38B | |
| -13.21% | 16.36B | |
| +5.41% | 13.97B | |
| +33.57% | 12.17B |
- Stock Market
- Equities
- PASG Stock
- Financials Passage Bio, Inc.
